// App-Quantinova.ai

289 : IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Clinton C Mason

Principal Investigators

  • Giuseppe Basso

  • Nicola E Potter

  • Lyndal Kearney

  • Anthony V. Moorman

  • Susana C. Raimondi

  • Sima Jeha

  • Ching-Hon Pui

  • William L. Carroll

  • Mignon L. Loh

  • Stephen P. Hunger

  • Hon-Chiu Eastwood Leung

  • Charles G Mullighan

  • Joshua D. Schiffman

  • Debra J. Morrison

  • Deepa Bhojwani

  • Phillip Barnette

  • Sarah T. South

  • Rodney R. Miles

  • Meenakshi Devidas

  • Andrea Pession

Medical Centers

  • Pediatric Neonatology, University of Utah, Salt Lake City, UT

  • Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom

  • Department of Pediatric Hematology and Oncology IRCCS, University of Pavia, Rome, Italy

  • Oncologia ed Ematologia Pediatrica Lalla Sera gnol-, Universita di Bologna, Bologna, Italy

  • Section of Haemato-Oncology, Institute of Cancer Research, London, United Kingdom

  • Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom

Locations

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Down syndrome

  • PDGFRA rearrangement

  • Solid malignancies

Biomarkers

  • Platelet Derived Growth Factor Receptor Alpha

  • White Blood Cell

Drug/Treatment

  • L-Tyrosine

  • Mofezolac

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved